1. pregnant or breastfeeding women, or women planning/desiring to become pregnant during the 28 days following enrolment into the study. 2. duration of self-reported symptoms of covid-19 for more than five days prior to screening. 3. signs of respiratory distress or severe disease prior to enrolment, including: 4. inability/unlikely to be in the study area for the duration of the 28-day follow-up period. 5. inability to tolerate oral medications. 6. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the patient or the objectives of the study. the investigator should make this determination in consideration of the volunteer's medical history. 7. the volunteer is assessed to be clinically unstable in the investigator's opinion. 8. participation in another investigational study involving an investigational product within 30 days, or 5 half-lives, whichever is longer, prior to screening. 9. personnel (e.g., investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log) directly involved in the conduct of the study. 10. any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that, in the investigator's judgment, might jeopardise the safety of the patient in the context of this study, or might interfere with study procedures or the ability of the subject to adhere to and complete the study. the investigator should make this determination in consideration of the volunteer's medical history.

1. pregnant or breastfeeding women, or women planning/desiring to become pregnant during the 28 days following enrolment into the study. 2. duration of self-reported symptoms of covid-19 for more than five days prior to screening. 3. signs of respiratory distress or severe disease prior to enrolment, including: 4. inability/unlikely to be in the study area for the duration of the 28-day follow-up period. 5. inability to tolerate oral medications. 6. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the patient or the objectives of the study. the investigator should make this determination in consideration of the volunteer's medical history. 7. the volunteer is assessed to be clinically unstable in the investigator's opinion. 8. participation in another investigational study involving an investigational product within 30 days, or 5 half-lives, whichever is longer, prior to screening. 9. personnel (e.g., investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log) directly involved in the conduct of the study. 10. any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that, in the investigator's judgment, might jeopardise the safety of the patient in the context of this study, or might interfere with study procedures or the ability of the subject to adhere to and complete the study. the investigator should make this determination in consideration of the volunteer's medical history.

pregnant or breastfeeding women, or women planning/desiring to become pregnant during the 28 days following enrolment into the study. duration of self-reported symptoms of covid-19 for more than five days prior to screening. signs of respiratory distress or severe disease prior to enrolment, including: inability/unlikely to be in the study area for the duration of the 28-day follow-up period. inability to tolerate oral medications. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the patient or the objectives of the study. the investigator should make this determination in consideration of the volunteer's medical history. the volunteer is assessed to be clinically unstable in the investigator's opinion. participation in another investigational study involving an investigational product within 30 days, or 5 half-lives, whichever is longer, prior to screening. personnel (e.g., investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log) directly involved in the conduct of the study. any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that, in the investigator's judgment, might jeopardise the safety of the patient in the context of this study, or might interfere with study procedures or the ability of the subject to adhere to and complete the study. the investigator should make this determination in consideration of the volunteer's medical history.

pregnant or breastfeeding women, or women planning/desiring to become pregnant during the 28 days following enrolment into the study. duration of self-reported symptoms of covid-19 for more than five days prior to screening. signs of respiratory distress or severe disease prior to enrolment, including: inability/unlikely to be in the study area for the duration of the 28-day follow-up period. inability to tolerate oral medications. any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the safety of the patient or the objectives of the study. the investigator should make this determination in consideration of the volunteer's medical history. the volunteer is assessed to be clinically unstable in the investigator's opinion. participation in another investigational study involving an investigational product within 30 days, or 5 half-lives, whichever is longer, prior to screening. personnel (e.g., investigator, sub-investigator, research assistant, pharmacist, study coordinator or anyone mentioned in the delegation log) directly involved in the conduct of the study. any physical, mental, or social condition, drug/alcohol use, history of illness or laboratory abnormality that, in the investigator's judgment, might jeopardise the safety of the patient in the context of this study, or might interfere with study procedures or the ability of the subject to adhere to and complete the study. the investigator should make this determination in consideration of the volunteer's medical history.